A Study of TopSpin360 Training Device
The Effectiveness of a Novel Neck Training Device on Objective Neck Strength and Cognitive Measures in Junior A Hockey Players
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Houston Hawkins
- Phone Number: 507-293-3295
- Email: hawkins.houston@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Houston Hawkins
- Phone Number: 507-293-3295
- Email: hawkins.houston@mayo.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Fluent English Speaker.
- Medically cleared to play ice hockey.
Exclusion Criteria:
- Clinically documented hearing issues.
- In-ear hearing aid or cochlear implant.
- Implanted pacemaker or defibrillator.
- Metal or plastic implants in skull. lack of verbal fluency in the English language.
- History of seizures.
- Allergy to rubbing alcohol or EEG gel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control Group
Subjects will receive no intervention for the duration of the hockey season.
|
|
|
Experimental: TopSpin360 Intervention Group
Subjects will use TopSpin360, twice- weekly and use for the duration of the hockey season.
|
Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in peak force
Time Frame: Baseline, post-season (approximately 6 months)
|
Measured by a neck isometric device, maximal load in kilograms that could be applied to head before deviation from neutral position.
|
Baseline, post-season (approximately 6 months)
|
|
Change in normalized peak force
Time Frame: Baseline, post-season (approximately 6 months)
|
Measured by a neck isometric device, peak force divided by participant weight in kilograms.
|
Baseline, post-season (approximately 6 months)
|
|
Change in force steadiness
Time Frame: Baseline, post-season (approximately 6 months)
|
Measured by a neck isometric device, average peak force.
|
Baseline, post-season (approximately 6 months)
|
|
Change in rate of force development (RFD)
Time Frame: Baseline, post-season (approximately 6 months)
|
Automatically collected by the TopSpin360 device, the multi-planar rate of force development (RFD) in pounds of force per second collected in both clockwise and counterclockwise.
|
Baseline, post-season (approximately 6 months)
|
|
Change in visuo-motor reaction time
Time Frame: Baseline, post-season (approximately 6 months)
|
Measured by a neck isometric device, reported in milliseconds (ms)
|
Baseline, post-season (approximately 6 months)
|
|
Change in N100 Amplitude
Time Frame: Baseline, post-season (approximately 6 months)
|
Electroencephalograph (EEG) recording of brain electrical activity N100 potential amplitude.
This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.
|
Baseline, post-season (approximately 6 months)
|
|
Change in N100 Latency
Time Frame: Baseline, post-season (approximately 6 months)
|
Electroencephalograph (EEG) recording of brain electrical activity N100 potential latency.
Increased latencies are indicative of slower responses.
Obtained by EEG recording of N100 potential amplitude.
This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.
|
Baseline, post-season (approximately 6 months)
|
|
Change in P300 Amplitude
Time Frame: Baseline, post-season (approximately 6 months)
|
Electroencephalograph (EEG) recording of brain electrical activity P300 potential amplitude.
This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.
|
Baseline, post-season (approximately 6 months)
|
|
Change in P300 Latency
Time Frame: Baseline, post-season (approximately 6 months)
|
Electroencephalograph (EEG) recording of brain electrical activity P300 potential latency.
Increased latencies are indicative of slower responses.
This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores
|
Baseline, post-season (approximately 6 months)
|
|
Change in N400 Amplitude
Time Frame: Baseline, post-season (approximately 6 months)
|
Electroencephalograph (EEG) recording of brain electrical activity N400 potential amplitude.
Increased amplitudes are indicative of larger signals.
This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.
|
Baseline, post-season (approximately 6 months)
|
|
Change in N400 Latency
Time Frame: Baseline, post-season (approximately 6 months)
|
Electroencephalograph (EEG) recording of brain electrical activity N400 potential latency.
Increased latencies are indicative of slower responses.
This measures is subsequently linearly transformed to a standardized score on a 0-100 scale, with larger peak amplitudes and shorter peak latencies resulting in higher scores.
|
Baseline, post-season (approximately 6 months)
|
|
Change in blood biomarker levels
Time Frame: Baseline, post-season (approximately 6 months)
|
Blood will be at a biomarker level.
We will investigate 5 different markers: NfL, SNCB, vWF, SNCA, and BDNF.
Each biomarker will be measured in Nanograms per Milliliter (ng/ml).
|
Baseline, post-season (approximately 6 months)
|
|
Change in salivary biomarkers
Time Frame: Baseline, post-season (approximately 6 months)
|
Salivary biomarkers are relatively new and we will investigate to see if NfL, SNCB, vWF, SNCA, and BDNF.
Each biomarker will be measured in Nanometer per milliliter (ng/ml).
|
Baseline, post-season (approximately 6 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in King-Devick Test (KDT) scores
Time Frame: Baseline, post-season (approximately 6 months)
|
A rapid number-naming test that requires individuals to read 3 numbered patters aloud as fast as possible, the resulting time if the KDT score.
The post-season score is compared to the pre-season baseline.
An increase in the number of seconds required to read the 3 number patterns is considered to be significant.
|
Baseline, post-season (approximately 6 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mario Hevesi, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 23-005197
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.